PEN
Penumbra, Inc.308.10
-1.05-0.34%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
12.07BP/E (TTM)
73.53Basic EPS (TTM)
4.19Dividend Yield
0%Recent Filings
8-K
Penumbra promotes Narayan to President
Penumbra appointed Shruthi Narayan as President effective September 1, 2025, promoting her from leading the interventional business where she drove neuro and vascular growth. With 20 years in medtech, including building Penumbra's vascular portfolio since 2013, she receives $2.5 million in RSUs vesting over four years. Adam Elsesser stays as CEO and Chairman. This internal rise signals steady leadership continuity amid expansion risks.
8-K
Q2 revenue up 13.4%
Penumbra reported Q2 2025 revenue of $339.5 million, up 13.4% from last year, fueled by 22.6% U.S. thrombectomy growth to $188.5 million and 42% VTE surge. Operating income hit $40.8 million with a 12.0% margin, rebounding from prior impairments. U.S. sales drove the gains, while international dipped. Full-year revenue guidance rose to $1.355–1.370 billion. Strong margins persist.
10-Q
Q2 FY2025 results
The provided 10-Q filing for Penumbra, Inc. contains only the cover page and table of contents, with no financial statements, MD&A, or notes included in the text between the markers. Without access to revenue, profitability, or balance sheet figures, key metrics like y/y or q/q deltas for revenue, EPS, or cash flow cannot be analyzed or reported. Non-GAAP metrics are not disclosed in the 10-Q. Liquidity, debt, M&A details, and risks remain unaddressed due to missing content. Investors should review the full filing for complete insights.
8-K
Board declassification approved
Penumbra filed an Amended and Restated Certificate of Incorporation and Third Amended and Restated Bylaws on May 28, 2025, following stockholder approval at the annual meeting. These changes phase in board declassification over three years, fully annualizing elections by the 2028 meeting, while ditching supermajority voting for key actions in favor of simple majority. Stockholders overwhelmingly backed both amendments, signaling strong support for enhanced governance flexibility. Declassification starts in 2026.
8-K
Q1 revenue surges 16.3%
Penumbra reported Q1 2025 revenue of $324.1 million, up 16.3% from last year, fueled by 25.0% U.S. thrombectomy growth to $187.9 million while international sales dipped slightly. Operating income hit $40.4 million with a 12.4% margin, boosted by better product mix and productivity. The company holds full-year revenue guidance at $1.34–1.36 billion. Strong U.S. demand drives momentum, yet forex headwinds linger.
ANGO
AngioDynamics, Inc.
13.48+0.14
CLPT
ClearPoint Neuro Inc.
13.82+1.44
EW
Edwards Lifesciences Corporatio
85.32+1.94
IART
Integra LifeSciences Holdings C
13.00-0.47
MDNC
MEDINOTEC INC
5.00+0.00
MDT
Medtronic plc.
97.72-0.85
NSPR
InspireMD Inc.
1.94-0.03
PACB
Pacific Biosciences of Californ
2.02-0.10
PAVM
PAVmed Inc.
0.31-0.01
VYCO
Vycor Medical, Inc.
0.16+0.00